Deep Lens, an artificial intelligence digital pathology company, received $14 million in funding to expand its AI platform for recruiting clinical trial participants.
The platform, called Viper, combines deep learning technology with pathology workflows to facilitate patient identification for clinical trials. The software, which aims to facilitate peer-to-peer collaboration and clinical research pathologists, can flag trial-eligible patients at the time of diagnosis.
"With this additional capital, we will move to quickly leverage our successes in the pathology industry and apply a highly disruptive approach to patient identification in clinical trials, one of the most expensive and time intensive issues faced by the pharmaceutical industry," Deep Lens President and co-founder Simon Arkell said in a news release.